Evidence map›Paper›PMID 41909709›Full record

ArticleFrontiers in immunology2026

AS01

Ferdinando Menezes, Shiyu Chen, Nicole Grunenberg, Mookho Malahleha, Kathy Mngadi, Monde Muyoyeta, Fatima Laher, Zvavahera Mike Chirenje, Linda-Gail Bekker, Paul Goepfert and 6 more

Abstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ferdinando MenezesCentro de Pesquisas Clinicas, University of Sao Paulo, Sao Paulo, Brazil.
Shiyu ChenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Nicole Grunenberg *Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Mookho Malahleha *Setshaba Research Centre, University of Cape Town, Cape Town, Soshanguve, South Africa.
Kathy Mngadi *Aurum Institute, Tembisa, Gauteng, South Africa.
Monde Muyoyeta *Centre for Infectious Diseases Research in Zambia, Livingstone, Zambia.
Fatima Laher *Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Zvavahera Mike Chirenje *Department of Obstetrics and Gynecology, University of California San Francisco, San Francisco, CA, United States.
Linda-Gail Bekker *Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Paul Goepfert *Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Glenda E Gray *Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Georgia Tomaras *Center for Human Systems Immunology, Duke University School of Medicine, Durham, NC, United States.
M Juliana McElrath *Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Esper KallasCentro de Pesquisas Clinicas, University of Sao Paulo, Sao Paulo, Brazil.
Alison C RoxbyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Zoe MoodieVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
Aurum Clinical Trials UnitUM1AI154463 · NIAID · AURUM INSTITUTE NPC · PI Gavin John Churchyard · 2021 to 2026
$8.1M
NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI069436NIAID NIH HHS UM1 AI154463
6 · The paper itself

Abstract

Introduction: Vaccine adjuvants are crucial in HIV vaccine development, enhancing immune responses. Immune responses generated by different adjuvanted vaccines are rarely compared directly with the same vaccine antigens. Methods: This retrospective cross-protocol, cross-sectional analysis examined four randomized, controlled, double-blinded, multicenter trials (HVTN 100, 107, 120, and 702) of adults without HIV who received the ALVAC-HIV (vCP2438) vaccine and a bivalent gp120 protein booster with either MF59, Alum, or AS01 Results: AS01 Conclusion: The AS01

Indexed as

Adjuvants, ImmunologicAdjuvants, VaccineAIDS VaccinesAlum CompoundsHIV-1HIV InfectionsImmunogenicity, VaccinePolysorbatesSqualeneAdultCD4-Positive T-LymphocytesCross-Sectional StudiesDouble-Blind MethodFemaleHIV AntibodiesHIV Envelope Protein gp120Adjuvants, ImmunologicAdjuvants, VaccineAIDS VaccinesAlum Compoundsaluminum sulfateHIV AntibodiesHIV Envelope Protein gp120Immunoglobulin GMF59 oil emulsionPolysorbatesProtein Subunit VaccinesSqualeneadjuvantalumAS01BHIVMF59vaccine

Identifiers

PMID41909709
PMCPMC13017943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.